Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: Focus on the Zilver PTX drug-eluting peripheral stent

Expert Review of Medical Devices

Volumn 12, Issue 2, 2015, Pages 157-162

  Moukarbel, George V ^a   Burket, Mark W ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

angioplasty; drug eluting stent; peripheral artery disease

Indexed keywords

ARTIFICIAL ORGANS; DISEASE CONTROL; PATIENT MONITORING; STENTS;

ANGIOPLASTY; BALLOON ANGIOPLASTY; DRUG-ELUTING STENTS; LONG-TERM OUTCOME; PERCUTANEOUS TREATMENT; PERIPHERAL ARTERIES; PERIPHERAL ARTERY DISEASE; RANDOMIZED TRIAL;

DISEASES;

PACLITAXEL;

ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENTING; DEVICE APPROVAL; DEVICE RECALL; DRUG ELUTING CARDIOVASCULAR STENT; FEMOROPOPLITEAL ARTERIAL STENOSIS; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; NEOINTIMA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG ELUTING STENT; ECONOMICS; FEMORAL ARTERY; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; STENOSIS, OCCLUSION AND OBSTRUCTION;

CLINICAL TRIALS AS TOPIC; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY;

EID: 84923695463     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2015.985653     Document Type: Article

References (24)

1. Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013;61(16):1736-43
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47(6): 1239-312
3. Rooke TW, Hirsch AT, Misra S, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(14):1555-70
4. Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12(6):683-95
5. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007; 69(6):910-19
6. Mwipatayi BP, Hockings A, Hofmann M, et al. Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis. J Vasc Surg 2008;47(2):461-9
7. Twine CP, Coulston J, Shandall A, McLain AD. Angioplasty versus stenting for superficial femoral artery lesions. Cochrane Database Syst Rev 2009(2):CD006767
8. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-Term results from the SIROCCO trial. J Endovasc Ther 2006;13(6):701-10
9. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16(3):331-8
10. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4(5):495-504
11. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96(2):636-45
12. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004;109(6):701-5
13. Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX Stents-evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol 2011; 22(5):603-10
14. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61(24): 2417-27
15. Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18(5):613-23
16. Fanelli F, Di Primo M, Boatta E, et al. Drug-eluting nitinol stent treatment of the superficial femoral artery and above-The-knee popliteal artery (the Zilver PTX single-arm clinical study): a comparison between diabetic and nondiabetic patients. Cardiovasc Intervent Radiol 2013;36(5):1232-40
17. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013;6(3):274-81
18. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S): S5-67
19. Bosiers M, Peeters P, Tessarek J, et al. The Zilver(R) PTX(R) Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino 2013;54(1):115-22
20. U.S. Food and Drug Administration. Recently-Approved Devices > Zilver-PTX- Drug-Eluting Peripheral Stent -P100022. Available from: www.fda.gov/MedicalDevices/ProductsandMedical Procedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm330293.htm Last updated 17 January 2014 [Accessed 19 May 2014]
21. U.S. Food and Drug Administration. Recalls, market withdrawals, & safety alerts > potential for delivery system catheter separation prompts cook medical to initiate voluntary global recall of Zilver- PTX- drug eluting stent. Available from: www.fda.gov/Safety/Recalls/ucm349421.htm Last updated 25 April 2013 [Accessed 19 May 2014]
22. Ishihara T, Iida O, Awata M, et al. Angioscopic assessment of early phase arterial repair after paclitaxel-coated nitinol drug-eluting stent implantation in the superficial femoral artery. Circ J 2013;77(7): 1838-43
23. De Cock E, Sapoval M, Julia P, et al. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France. Cardiovasc Intervent Radiol 2013;36(2):362-70
24. Evaluation of paclitaxel eluting stent vs paclitaxel eluting balloon treating peripheral artery disease of the femoral artery. Available from: http://clinicaltrials.gov/show/NCT01728441